Efficacy and Safety of Indwelling Catheter for Malignant Pleural Effusions Related to Timing of Cancer Therapy: A Systematic Review

Autores da FMUP
Participantes de fora da FMUP
- Porcel, JM
- Cordovilla, R
- Tazi-Mezalek, R
- Barrios-Barreto, D
- Pérez-Pallarés, J
- Martínez-Tomás, R
- Flandes-Aldeyturriaga, J
- Cases-Viedma, E
- Recalde, B
- Botana-Rial, M
Unidades de investigação
Abstract
Introduction: To compare the efficacy and safety of indwelling pleural catheters (IPC) in relation with the timing of systemic cancer therapy (SCT) (i.e., before, during, or after SCT) in patients with malignant pleural effusion (MPE).Methods: Systematic review of randomized controlled trials (RCT), quasi-controlled trials, prospective and retrospective cohorts, and case series of over 20 patients, in which the timing of IPC insertion in relation to that of SCT was provided. Medline (via PubMed), Embase, and Cochrane Library were systematically searched from inception to January 2023. The risk of bias was assessed using the Cochrane Risk of Bias (ROB) tool for RCTs and the ROB in non-randomized studies of interventions (ROBINS-I) for non-randomized designs.Results: Ten studies (n = 2907 patients; 3066 IPCs) were included. Using SCT while the IPC was in situ decreased overall mortality, increased survival time, and improved quality-adjusted survival. Timing of SCT had no effect on the risk of IPC-related infections (2.85% overall), even in immunocompromised patients with moderate or severe neutropenia (relative risk 0.98 [95%CI: 0.93-1.03] for patients treated with the combination of IPC and SCT). The inconsistency of the results or the lack of analysis of all outcome measures in relation to the SCT/IPC timing precluded drawing solid conclusions about time to IPC removal or need of re-interventions.Conclusions: Based on observational evidence, the efficacy and safety of IPC for MPE does not seem to vary depending on the IPC insertion timing (before, during, or after SCT). The data most likely support early IPC insertion.(c) 2023 SEPAR. Published by Elsevier Espan similar to a, S.L.U. All rights reserved.
Dados da publicação
- ISSN/ISSNe:
- 1579-2129, 0300-2896
- Tipo:
- Review
- Páginas:
- 566-574
Archivos de Bronconeumologia Ediciones Doyma, S.L.
Citações Recebidas na Web of Science: 1
Documentos
- Não há documentos
Filiações
Keywords
- Malignant pleural effusion; Indwelling pleural catheter; Chemotherapy; Efficacy; Safety
Financiamento
Proyectos asociados
Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG) -NCT05635032
Investigador Principal: Hélder Novais e Bastos
Estudo Observacional Académico (FIBRALUNG) . FCT . 2021
MCP1 as a prognostic biomarker in Hypersensitivity Pneumonitis: a prospective study
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico (Pneumonitis) . 2023
Chronic Bronchopulmonary aspergillosis patients with underlying chronic obstructive pulmonary disease: providing grounds for biomarkers search through clinical phenotyping
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Impact of Chronic Obstructive Pulmonary Disease in surgical outcomes of lung cancer patients undergoing curative intent surgery
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2021
Pulmonary Emphysema Regional Distribution and Extent from Chest Computed Tomography is Associated with Pulmonary Function Impairment in COPD Patients.
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2021
Non-invasive assessment of Benign Tracheal Stenosis.
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2020
Predictors of lung entrapment in malignant pleural effusion
Investigador Principal: Hélder Novais e Bastos
Estudo Clínico Académico . 2022
Citar a publicação
Porcel JM,Cordovilla R,Tazi R,Barrios D,Pérez J,Bastos H,Martínez R,Flandes J,Cases E,Recalde B,Botana M. Efficacy and Safety of Indwelling Catheter for Malignant Pleural Effusions Related to Timing of Cancer Therapy: A Systematic Review. Arch. Bronconeumol. 2023. 59(9):p. 566-574. IF:8,000. (1).